This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis
Sponsor: AnaptysBio, Inc.
Terminated
ANB032 did not meet the primary endpoint in moderate-to-severe atopic dermatitis
Listed as NCT05935085, this PHASE2 trial focuses on Atopic Dermatitis Eczema and remains terminated or withdrawn. Sponsored by AnaptysBio, Inc., it has been updated 9 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Study Description(click to expand)This is a Phase 2, randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
This is a Phase 2, randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE2
-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Mar 2025 — Sep 2025 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Nov 2023 — May 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Nov 2023 [monthly]
Recruiting PHASE2
First recorded
Jun 2023
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AnaptysBio, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .